

ASX ANNOUNCEMENT

15 November 2019

Retraction of Statements – Next Tech Stock Article

Medical technology company, **HeraMED Limited (ASX:HMD)** ("HeraMED" or the "Company") refers to the Company's response issued on 14 November to the ASX price and volume query received on 14 November.

In response to question 3 of the ASX price and volume query, HeraMED responded "HMD is aware of an article that was commissioned by HMD and that was released on the Next Tech Stock website today (**Article**). HMD notes that the Article had a manifestly incorrect typographical error, in that it incorrectly referred to HMD as being a "...this \$13 billion capped Aussie junior....". HMD was not aware of the timing of the release of the Article prior to such release this morning."

The Company notes that it had commissioned and paid for the Article and that the Article included references to revenue projections for the Company (**Forecasts**). The Company acknowledges that there was no reasonable basis for making the Forecasts.

Following consultation with the ASX, the Company advises that it retracts, without any admission of liability, the Forecasts (**Retracted Information**) made in the Article. The Company advises that the publisher of the Article has confirmed that the Article has been overwritten and the Retracted Information has been removed.

As a consequence of this retraction, the Company advises that the Retracted Information should be disregarded and that accordingly investors should not rely on the Retracted Information for their investment decisions.

-ENDS-

HeraMED Limited

CEO and Co-Founder

David Groberman

M: +972-52-6991188

E: David@hera-med.com

Company Secretary

Stephen Buckley

T: +61 (0)8 6189 1155

E: stephen@companysecsol.com.au

Released through: Henry Jordan, Six Degrees Investor Relations, +61 431 271 538

About HeraMED Limited (ASX:HMD):

HeraMED is an innovative medical Data and Technology company leading the digital transformation of prenatal care. HeraMED utilises the digital health ecosystem including clinical home monitoring devices, cloud computing, artificial intelligence, big data and digital social networking to reshape the Doctor/Patient relationship. The company is revolutionizing the pregnancy experience by empowering personalized, continuous and proactive home monitoring, to deliver better care at a lower cost. Keeping pregnant mothers engaged, informed and well-supported provides reassurance and peace of mind while allowing the healthcare providers to work at their highest levels of ability and enabling early detection of potential risks.